Endpoint surrogacy in oncology Phase 3 randomised controlled trials.

Area of Science:

• Oncology
• Clinical Trials
• Biostatistics

Background:

• Endpoint surrogacy is crucial in clinical oncology research.
• Overall survival is the traditional gold standard but can lead to lengthy trials.

Discussion:

• Using PFS as a primary endpoint can accelerate drug approval timelines.
• Faster approvals mean earlier access to potentially life-saving therapies for cancer patients.
• This approach balances the need for timely treatment with rigorous scientific evaluation.

Key Insights:

• Surrogate endpoints offer a faster route to drug approval compared to overall survival.
• Earlier drug availability can significantly benefit patients awaiting treatment options.
• The strategic use of PFS can optimize the drug development process.

Outlook:

• Further validation of surrogate endpoints in diverse cancer types is warranted.
• Continued research into predictive biomarkers for PFS and OS is essential.
• Policy and regulatory frameworks may adapt to incorporate surrogate endpoints more broadly.